3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
4
Carcinoma, Hepatocellular
4
Recurrence
3
Respiratory Tract Infections
2
Neoplasms
2
Lymphoma, Follicular
2
Hepatitis C, Chronic
2
Hepatitis C
2
Head and Neck Neoplasms
2
Wilms Tumor
1
Testicular Neoplasms
1
Teratoma, Testicular
1
Teratoma
1
Seminoma
1
Respiratory Syncytial Virus Infections
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pneumonia
1
Neuroblastoma
1
Neoplasms, Squamous Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
Cyclophosphamide
227
Cytarabine
194
fludarabine phosphate
138
Methotrexate
132
Filgrastim
127
Busulfan
103
Etoposide
99
Peripheral Blood Stem Cell Transplantation
91
Rituximab
81
fludarabine
77
Radiotherapy
77
Vincristine
74
Daunorubicin
68
Antilymphocyte Serum
65
Cyclosporine
63
Dexamethasone
61
Tacrolimus
56
Mycophenolic Acid
53
Melphalan
52
Imatinib Mesylate
50
Granulocyte Colony-Stimulating Factor
50
Mercaptopurine
46
Whole-Body Irradiation
45
Idarubicin
43
sargramostim
42
Methylprednisolone
42
Doxorubicin
41
Flow Cytometry
40
Prednisone
39
Clofarabine
39
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia
×
Ribavirin
×
Clear all
NCT00559091
2022-12-22
Borden-001
Jewish General Hospital
Phase 2
Completed
18 enrolled